Idera Pharmaceuticals Inc (NASDAQ:IDRA) reported its financial and operational results for the fourth quarter and year ended December 31, 2013. Net loss applicable to common stockholders for the three months ended December 31, 2013 was $6.4 million, or $0.10 per diluted share, compared to a net loss applicable to common stockholders of $6.5 million, or $0.24 per diluted share, for the same period in 2012. On last trading day Idera Pharmaceuticals Inc (NASDAQ:IDRA) ended up -21.22% lower to close at $4.79 while trading in the range of $4.50 – $5.98. Its return on assets (ROA) is -114.30%. Idera Pharmaceuticals Inc (NASDAQ:IDRA) monthly performance is -20.17%.
Arrowhead Research Corp (NASDAQ:ARWR)‘s stock had its “buy” rating reaffirmed by stock analysts at Deutsche Bank in a report issued on Monday, American Banking News.com reports. Arrowhead Research Corp (NASDAQ:ARWR) in last trading activity ended up at $17.37 with day range of $15.97 – $21.09. Company weekly performance is -23.38% while its quarterly performance stands at 84.98%. Arrowhead Research Corp (NASDAQ:ARWR) is -37.13% away from its 52 week high.
FireEye Inc. (NASDAQ:FEYE) claims it is moving from a “category creator” to a “category consolidator” as it readies partners for a mid-market push. FireEye Inc (NASDAQ:FEYE) belongs to Technology sector with market capitalization of 9.15 B and has 7.00% insider ownership. In last trading activity company’s stock closed at $63.50 while opening price was $68.00.
Stock analysts at JMP Securities hoisted their price target on shares of Horizon Pharma (NASDAQ:HZNP) from $18.00 to $22.00 in a report issued on Thursday, Stock Ratings Network.com reports. The firm currently has an “outperform” rating on the stock. On Monday shares of Horizon Pharma Inc (NASDAQ:HZNP) opened at $17.30 and closed at $15.65. This year Company’s Earnings per Share (EPS) growth is 82.00% and next year’s estimated EPS growth is 155.06%. Analysts mean target price for Horizon Pharma Inc (NASDAQ:HZNP) is $21.00.
Leave a Reply